Avita Medical and Stedical Scientific have entered an exclusive multi-year distribution agreement to commercialise PermeaDerm biosynthetic wound matrix in the US.
PermeaDerm is a biosynthetic matrix that promotes wound healing while providing a high level of permeability and biocompatibility.
The wound matrix is authorised by the US Food and Drug Administration (FDA) as a transparent matrix to treat a range of wound types until healing is achieved.
As per the agreement, Avita Medical will be the only company authorised to promote, sell, and distribute PermeaDerm products in the US, including any upgrades or modifications that may be made in the future.
The distribution agreement is intended for five years, and if specified minimums are met, there is a possibility to extend for a further five years.
The company projects that the gross margin on PermeaDerm sales will be 50% of the average sales price.
Avita Medical CEO Jim Corbett said: “Our partnership with Stedical Scientific is an important step in expanding our portfolio and addressing the unmet needs of our patients.
“Avita Medical and Stedical Scientific are ideal partners given the complementary nature of our products, the overlap of call points, and the strength of our footprint and sales force.
“We anticipate these synergies will allow us to effectively leverage our established commercial presence, enhancing the integration of PermeaDerm into our portfolio.
“This strategic collaboration underscores our commitment to delivering innovative solutions and improving outcomes for those we serve.”
PermeaDerm can be used to promote healing in burn or wound operations treated with Spray-On Skin Cells from the RECELL System.
In the US, the biosynthetic wound matrix can be reimbursed in both inpatient and outpatient settings.
Stedical Scientific chairman Lin Sun said: “We are thrilled to mark this important growth milestone with Avita Medical, who shares our goal of treating millions of patients suffering from a broad spectrum of wounds.
“Avita Medical has an established presence in the US wound care market, further validating the clinical and commercial value of PermeaDerm.
“This collaboration will expand our reach to more patients, physicians, and hospitals with a compelling portfolio of solutions that improve care and surgical performance. We look forward to a long and successful partnership.”
